TYK Medicines Plans HK$ 288.8 Million Share Placement

• TYK Medicines agreed November 12, 2026, to issue 76,000,000 H Shares at HK$ 3.8 each, raising HK$ 288.8 million.
• Qilu will subscribe for 57,000,000 shares, taking a 12.5% stake; CVG Global will purchase 19,000,000 shares for a 4.17% holding.
• The subscription price represents a 7.32% discount to the November 12 closing price; new shares represent 16.66% of enlarged share capital.
• Net proceeds of approximately HK$ 288.42 million will primarily fund TY-0540 ovarian and breast cancer clinical trials.
• Completion is subject to conditions, including listing approval, with a January 29, 2027, deadline unless extended.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261112-12410654), on November 12, 2026, and is solely responsible for the information contained therein.